[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100291989":3},{"organization":4,"outcomesModule":7,"designInfo":21,"detailedDescription":28,"studyPopulation":20,"armGroups":29,"interventions":37,"overallOfficials":48,"centralContacts":52,"locations":57,"responsibleParty":71,"collaborators":20,"id":74,"slug":20,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":20,"eligibilityCriteria":78,"healthyVolunteers":75,"sex":79,"minAge":80,"maxAge":20,"enrollmentInfo":81,"targetDuration":20,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":59,"whyStopped":20,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"University of Louisville","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":20},[9],{"measure":10,"description":11,"timeFrame":12},"Safety and Tolerability of Combination Irreversible Electroporation and Nivolumab Treatment","Adverse events and Serious adverse events will be collected","Baseline thru 100 days after receiving last dose",[14,18],{"measure":15,"description":16,"timeFrame":17},"Progression Free Survival","CT scans will be reviewed","Every three months for 4 years.",{"measure":19,"description":16,"timeFrame":17},"Overall Survival",null,{"allocation":22,"interventionModel":23,"interventionModelDescription":24,"primaryPurpose":25,"observationalModel":20,"timePerspective":20,"maskingInfo":26},"NA","SINGLE_GROUP","All patients will undergo irreversible electroporation and treatment with Nivolumab","TREATMENT",{"masking":27,"maskingDescription":20,"whoMasked":20},"NONE","Immunotherapy and irreversible electroporation in the treatment of advanced pancreatic adenocarcinoma. This is a Phase II study in which all patients undergoing irreversible electroporation of locally advanced pancreatic adenocarcinoma will be treated with nivolumab post-operatively.",[30],{"label":31,"type":32,"description":33,"interventionNames":34},"Single Arm","EXPERIMENTAL","All patients undergoing irreversible electroporation will be treated with nivolumab",[35,36],"Drug: Nivolumab","Procedure: Irreversible Electroporation",[38,43],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":20},"DRUG","Nivolumab","Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.",[31],{"type":44,"name":45,"description":46,"armGroupLabels":47,"otherNames":20},"PROCEDURE","Irreversible Electroporation","Non-thermal ablation of tumor",[31],[49],{"name":50,"affiliation":5,"role":51},"Robert Martin, MD, PhD","PRINCIPAL_INVESTIGATOR",[53],{"name":50,"role":54,"phone":55,"phoneExt":20,"email":56},"CONTACT","502-629-3355","robert.martin@louisville.edu",[58],{"facility":5,"status":59,"city":60,"state":61,"zip":62,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":20},"RECRUITING","Louisville","Kentucky","40202","United States","US",{"type":66,"coordinates":67},"Point",[68,69],-85.75941,38.25424,{"lat":69,"lon":68},{"type":51,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Robert C. Martin","Principal Investigator","100291989",false,"NCT03080974","Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* ≥ 18 years if age\n* Diagnosed with stage III pancreatic cancer\n* Tumor is measurable\n* Glomerular Filtration Rate \\> 60 m\u002FL\u002Fmin\u002F1.73 m(2)\n* Willing and able to comply with the protocol requirements\n* Able to comprehend and have signed the informed consent to participate\n\nExclusion Criteria:\n\n* Participating in another clinical trial for the treatment of cancer at time of screening\n* Are pregnant or currently breast feeding\n* Have a cardiac pacemaker or Implantable Cardioverter Defibrillator implanted that cannot be deactivated during the procedure\n* Have non-removable implants with metal parts within 1 cm of the target lesion\n* Had a myocardial infarction within 3 months prior to enrollment","ALL","18 Years",{"count":82,"type":83},10,"ESTIMATED","INTERVENTIONAL",[86],"PHASE2","Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.",[89],"Pancreatic Adenocarcinoma",[91,40],"irreversible electroporation","2025-10-27",{"date":94,"type":95},"2025-10-29","ACTUAL",{"date":97,"type":95},"2017-08-14",{"date":99,"type":83},"2029-04-01",{"name":5,"class":6},1]